Advanced Glycation End Products Market Size to Hit USD 2.30 Billion by 2027

According to Nova one advisor, the global Advanced Glycation End Products market was valued at USD 1.50 Billion in 2020 and it is expected to hit around USD 2.30 billion by 2030 with a CAGR of 5.0% during the forecast period 2022 to 2030.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/5918

Advanced Glycation End Products Market: Overview

• Advanced glycation end products (AGEs) are a group of compounds that are usually developed via non-enzymatic reactions that occur between the carbonyl groups of reducing sugars & the free lipids, amino groups of proteins, or nucleic acids. They could be derived exogenously from diet or by endogenously inside the body. Advanced glycation end products form intracellular and extracellular inside every tissues and body fluids and are capable of cross-linking with other proteins, which can affect their normal mechanism or functions.
• Aging is the progressive accumulation of damage to an organism over time, leading to disease and death. Recently, advanced glycation end products (AGEs) have received particular attention. AGEs are formed in high amounts in diabetes, but also in the physiological organism during aging.
• AGEs seem to widely accumulate in extrinsically aged skin. The role of advanced glycation end products (AGEs) has been increasingly discussed in skin aging, and the potential of anti-AGE strategies has received high interest from pharmaceutical companies for the development of novel anti-aging cosmeceuticals compounds.
• In the skin, glycation accounts for accelerated aging, yellowing and stiffness, and decreased circulation. Skin cannot look young and healthy with glycation products and treatment is best started with prevention by diet control, reducing total calories, and avoiding high sugar foods. However, supplements such as aminoguanidine, pyridoxamine, carnosine, and benfotiamine are excellent glycation preventers and are already gaining traction in the cosmetic industry. As noted, topical products to treat glycation thus far are few and not very effective; however, a recent approach measuring Pentosidine in the skin suggests a new approach to skin care and anti-aging treatments.
• Rising incidence of cancer globally is driving the market, as advanced glycation end products majorly raise the level of inflammation in the body, which has been associated with the development of cancer. For instance, according to the National Cancer Institute, 2019, an estimated 1,762,450 new cases of cancer were diagnosed globally, with around 606,880 deaths from the disease.
• Rising incidences of neurodegenerative disorders including Alzheimer’s, Parkinson’s diseases, etc. is anticipated to fuel the market during the forecast period, as advanced glycation end products are proteins that get glycated after exposure to sugars, which further contributes to the development of neurodegenerative disorders.

Report Coverage

Market Segmentation: Advanced Glycation End Products Market

• In terms of type, the global advanced glycation end products market has been classified into non-fluorescent AGEs, fluorescent AGEs, and others. The fluorescent AGEs segment can be further sub-segmented into Pentosidine and Methylglyoxal-lysine dimer (MOLD). The non-fluorescent AGEs segment can be further split into Carboxymethyl-lysine (CML), Carboxyethyl-lysine (CEL), and Pyrraline.
• Based on application, the global advanced glycation end products market has been categorized into diabetes complications, cancer, bone diseases, neurodegenerative diseases, and others
• In terms of end user, the global advanced glycation end products market has been classified into hospitals, specialty clinics, and others
• Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The advanced glycation end products market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2027, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2027, along with market size estimations.

Regional Overview: Advanced Glycation End Products Market

• In terms of region, the global advanced glycation end products market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
• Rise in prevalence of lifestyle diseases and increase in healthcare expenditure are anticipated to boost the market in North America during the forecast period. According to the Centers for Disease Control and Prevention, presently, over 100 million adults in the U.S. are living with diabetes or prediabetes. About 1.4 million new cases of diabetes are diagnosed in the U.S. every year. More than one in every 10 adults aged 20 or older has diabetes.
• The market in Latin America is projected to expand at a steady pace, owing to the presence of rapidly developing economies, along with enhanced healthcare infrastructure in the region. The market in Brazil is anticipated to expand at a significant growth rate during the forecast period due to the rising life science-regarding research and development of healthcare infrastructure in the country.
• The current and expected market revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2021 to 202, with their CAGRs from 2021 to 2027
• The study also offers a list of recommendations, highlights, and useful insights of the global advanced glycation end products market, which would help new companies willing to enter the market and existing companies to increase market shares and in the decision-making process

Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/5918

Some of the prominent players in the Advanced Glycation End Products Market include: AbbVie, Inc. (Allergan Plc), Merck KGaA, Takeda Pharmaceutical Company Limited, Estée Lauder Companies, Shiseido Company, Limited, Beiersdorf AG, L’Oreal S.A., NuFACE, Rodan & Fields, PhotoMedex, Inc., Ostium Cosmetics, Cell Biolabs, Inc., and Shanghai Korain Biotech Co., Ltd.

Unravelling the Critical Segments

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:

Global Advanced Glycation End Products Market: Segmentation

• Advanced Glycation End Products Market, by Type
  • Non-fluorescent AGEs
    • Carboxymethyl-lysine (CML)
    • Carboxyethyl-lysine (CEL)
    • Pyrraline
  • Fluorescent AGEs
    • Pentosidine
    • Methylglyoxal-lysine dimer (MOLD)
• Advanced Glycation End Products Market, by Application
  • Diabetic Complications
  • Cancer
  • Bone Diseases
  • Neurodegenerative Diseases
  • Others
• Advanced Glycation End Products Market, by End User
  • Hospitals
  • Specialty Clinics
  • Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/